DHR:NYE-Danaher Corporation (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 205.16

Change

+4.77 (+2.38)%

Market Cap

USD 151.57B

Volume

2.97M

Analyst Target

USD 220.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
A Agilent Technologies Inc

+1.94 (+1.70%)

USD 36.12B
IQV IQVIA Holdings Inc

+3.13 (+1.83%)

USD 33.79B
LH Laboratory Corporation of Amer..

+3.72 (+1.60%)

USD 21.18B
DGX Quest Diagnostics Incorporated

-1.32 (-0.78%)

USD 18.88B
CRL Charles River Laboratories

+3.29 (+2.25%)

USD 9.00B
QGEN Qiagen NV

+0.52 (+1.32%)

USD 8.30B
ENZ Enzo Biochem Inc

-0.01 (-2.21%)

USD 0.03B
TMO Thermo Fisher Scientific Inc

+6.09 (+1.26%)

N/A
WAT Waters Corporation

+6.64 (+1.87%)

N/A
MTD Mettler-Toledo International I..

+16.12 (+1.39%)

N/A

ETFs Containing DHR

AILG 6.99 % 0.00 %

N/A

N/A
SYNB Putnam Biorevolution ETF 6.25 % 0.00 %

+0.30 (+0.79%)

USD 5.09M
LIFE-U:CA Evolve Global Healthcare .. 5.53 % 0.00 %

-0.58 (0.79%)

N/A
ZWHC:CA BMO Covered Call Health C.. 4.69 % 0.00 %

-0.61 (0.79%)

N/A
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.49 % 0.00 %

-0.42 (0.79%)

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.34 % 0.00 %

-0.23 (0.79%)

N/A
WHCS:SW iShares MSCI World Health.. 4.21 % 0.00 %

N/A

N/A
YALL God Bless America ETF 4.17 % 0.00 %

+0.49 (+0.79%)

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.11 % 0.00 %

-0.19 (0.79%)

N/A
CBUF:F iShares V Public Limited .. 4.06 % 0.00 %

-0.05 (0.79%)

N/A
SANE 3.95 % 0.00 %

N/A

N/A
BCHP EGSHARES BLUE CHIP ETF EG.. 3.38 % 0.00 %

+0.42 (+0.79%)

USD 0.12B
XUHC:SW 3.16 % 0.00 %

N/A

N/A
IUHC:SW iShares S&P 500 Health Ca.. 3.06 % 0.00 %

-0.09 (0.79%)

N/A
GXLV:LSE SPDR® S&P® U.S. Health .. 3.06 % 0.00 %

-0.38 (0.79%)

N/A
CNEQ The Alger ETF Trust 2.83 % 0.00 %

+0.33 (+0.79%)

N/A
INNO 2.76 % 0.00 %

N/A

N/A
BKDV BNY Mellon ETF Trust II 2.62 % 0.00 %

+0.20 (+0.79%)

USD 0.20B
USRI:LSE 2.50 % 0.00 %

N/A

N/A
UPVLD:SW 2.35 % 0.00 %

N/A

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.30 % 0.00 %

-0.08 (0.79%)

N/A
XMLH:F Legal & General Ucits Etf.. 1.94 % 0.00 %

-0.12 (0.79%)

N/A
WEBD:XETRA AMUNDI MSCI USA SRI Clima.. 1.92 % 0.00 %

-0.14 (0.79%)

N/A
HYLG 1.44 % 0.00 %

N/A

N/A
LESW:LSE 1.38 % 0.00 %

N/A

N/A
WSRI:LSE 1.30 % 0.00 %

N/A

N/A
WELB:XETRA Amundi MSCI ACWI SRI PAB .. 1.08 % 0.00 %

+0.04 (+0.79%)

N/A
CWW.A:CA 0.00 % 1.49 %

N/A

N/A
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

+0.31 (+0.79%)

N/A
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

+0.37 (+0.79%)

N/A
JHMH 0.00 % 0.46 %

N/A

N/A
RAVI FlexShares Ready Access V.. 0.00 % 0.25 %

-0.04 (0.79%)

USD 1.24B
JMIN 0.00 % 0.12 %

N/A

N/A
EVSTC 0.00 % 0.00 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

N/A

CAD 0.05B
LS:CA 0.00 % 2.21 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

+0.69 (+0.79%)

N/A
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

+1.99 (+0.79%)

N/A
MIVG:CA Mackenzie Ivy Global Equi.. 0.00 % 0.89 %

+0.02 (+0.79%)

CAD 0.02B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

-10.75 (0.79%)

N/A
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

-0.37 (0.79%)

N/A
XDWH:LSE Xtrackers MSCI World Heal.. 0.00 % 0.00 %

-0.46 (0.79%)

N/A
EMWE:F BNP Paribas Easy - MSCI W.. 0.00 % 0.00 %

+0.28 (+0.79%)

N/A
GNAR:F 0.00 % 0.00 %

N/A

N/A
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
XAMB:F Amundi Index Solutions - .. 0.00 % 0.00 %

+1.13 (+0.79%)

N/A
DXSF:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

-0.01 (0.79%)

USD 0.08B
EWRD:XETRA 0.00 % 0.00 %

N/A

N/A
GNAR:XETRA 0.00 % 0.00 %

N/A

N/A
QDVG:XETRA iShares S&P 500 Health Ca.. 0.00 % 0.00 %

-0.13 (0.79%)

N/A
VMOM:XETRA 0.00 % 0.00 %

N/A

N/A
XUHC:XETRA Xtrackers MSCI USA Health.. 0.00 % 0.00 %

-0.64 (0.79%)

N/A
ZPDH:XETRA SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

-0.48 (0.79%)

N/A
NUSA:CA NBI Active U.S. Equity ET.. 0.00 % 0.00 %

+0.18 (+0.79%)

CAD 0.07B
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

-0.06 (0.79%)

N/A
XOUT GraniteShares XOUT U.S. L.. 0.00 % 0.00 %

N/A

N/A
MEDTE:PA BNP Paribas Easy ECPI Glo.. 0.00 % 0.00 %

-0.10 (0.79%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.63% 50% F 17% F
Dividend Return 0.14% 50% F 3% F
Total Return -10.49% 42% F 17% F
Trailing 12 Months  
Capital Gain -16.04% 42% F 17% F
Dividend Return 0.46% 43% F 7% C-
Total Return -15.57% 42% F 16% F
Trailing 5 Years  
Capital Gain 71.23% 55% F 55% F
Dividend Return 3.75% 40% F 6% D-
Total Return 74.99% 55% F 46% F
Average Annual (5 Year Horizon)  
Capital Gain 4.26% 33% F 50% F
Dividend Return 4.63% 33% F 43% F
Total Return 0.37% 43% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 27.37% 58% F 37% F
Risk Adjusted Return 16.92% 33% F 33% F
Market Capitalization 151.57B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.